Balentine LLC’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-25,653
| Closed | -$1.1M | – | 339 |
|
|
2024
Q1 | $1.1M | Buy |
25,653
+204
| +0.8% | +$8.41K | 0.03% | 177 |
|
|
2023
Q4 | $943K | Buy |
25,449
+3,032
| +14% | +$109K | 0.03% | 178 |
|
|
2023
Q3 | $813K | Buy |
22,417
+672
| +3% | +$23.9K | 0.03% | 186 |
|
|
2023
Q2 | $775K | Sell |
21,745
-1,944
| -8% | -$69.7K | 0.03% | 203 |
|
|
2023
Q1 | $843K | Sell |
23,689
-1,234
| -5% | -$43.2K | 0.03% | 212 |
|
|
2022
Q4 | $876K | Buy |
24,923
+7,079
| +40% | +$236K | 0.03% | 228 |
|
|
2022
Q3 | $525K | Sell |
17,844
-14,830
| -45% | -$562K | 0.02% | 283 |
|
|
2022
Q2 | $1.78M | Buy |
32,674
+13,732
| +72% | +$758K | 0.07% | 128 |
|
|
2022
Q1 | $1.03M | Buy |
18,942
+7,448
| +65% | +$405K | 0.04% | 165 |
|
|
2021
Q4 | $634K | Buy |
11,494
+4,535
| +65% | +$236K | 0.02% | 139 |
|
|
2021
Q3 | $332K | Buy |
6,959
+2,577
| +59% | +$129K | 0.01% | 169 |
|
|
2021
Q2 | $218K | Buy |
+4,382
| New | +$211K | 0.01% | 157 |
|
|
2020
Q3 | – | Sell |
-2,121
| Closed | -$108K | – | 455 |
|
|
2020
Q2 | $108K | Buy |
+2,121
| New | +$109K | 0.01% | 143 |
|
|
2019
Q4 | – | Sell |
-857
| Closed | -$46K | – | 658 |
|
|
2019
Q3 | $46K | Hold |
857
| – | – | ﹤0.01% | 139 |
|
|
2019
Q2 | $43K | Sell |
857
-74
| -8% | -$3.71K | ﹤0.01% | 120 |
|
|
2019
Q1 | $49K | Buy |
931
+391
| +72% | +$19.5K | ﹤0.01% | 119 |
|
|
2018
Q4 | $26K | Hold |
540
| – | – | ﹤0.01% | 167 |
|
|
2018
Q3 | $27K | Sell |
540
-196
| -27% | -$9.96K | ﹤0.01% | 112 |
|
|
2018
Q2 | $37K | Buy |
736
+412
| +127% | +$20.8K | ﹤0.01% | 34 |
|
|
2018
Q1 | $16K | Sell |
324
-3,857
| -92% | -$180K | ﹤0.01% | 20 |
|
|
2017
Q4 | $185K | Sell |
4,181
-1,660
| -28% | -$76.7K | 0.01% | 130 |
|
|
2017
Q3 | $296K | Buy |
5,841
+1,490
| +34% | +$75.6K | 0.02% | 84 |
|
|
2017
Q2 | $235K | Hold |
4,351
| – | – | 0.02% | 98 |
|
|
2017
Q1 | $229K | Buy |
4,351
+453
| +12% | +$23K | 0.02% | 97 |
|
|
2016
Q4 | $188K | Sell |
3,898
-8,252
| -68% | -$408K | 0.02% | 102 |
|
|
2016
Q3 | $655K | Buy |
12,150
+8,252
| +212% | +$452K | 0.09% | 29 |
|
|
2016
Q2 | $211K | Buy |
3,898
+1,010
| +35% | +$53.2K | 0.04% | 78 |
|
|
2016
Q1 | $146K | Hold |
2,888
| – | – | 0.04% | 68 |
|
|
2015
Q4 | $146K | Buy |
2,888
+602
| +26% | +$30.7K | 0.03% | 88 |
|
|
2015
Q3 | $110K | Buy |
2,286
+198
| +9% | +$10.3K | 0.02% | 91 |
|
|
2015
Q2 | $109K | Sell |
2,088
-684
| -25% | -$38.5K | 0.02% | 84 |
|
|
2015
Q1 | $160K | Buy |
+2,772
| New | +$159K | 0.03% | 66 |
|
Other funds holding GSK
JEST
Balentine LLC's GSK Position: Q2 2024 in Review
Balentine LLC sold out of GSK (GSK) in Q2 2024, closing a stake of 25,653 shares — an estimated $1.1M sold.
Balentine LLC first reported a position in GSK in Q1 2015 and held it in 32 quarters. The position peaked at $1.78M in Q2 2022. 884 funds tracked by Wall St. Rank hold GSK as of Q2 2024.
- Balentine LLC reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
- Balentine LLC sold 25,653 GSK shares in Q2 2024, an estimated $1.1M.
- Balentine LLC first reported a position in GSK in Q1 2015 and held it in 32 quarters.
- Balentine LLC's GSK position peaked at $1.78M in Q2 2022.
- 884 funds tracked by Wall St. Rank held GSK as of Q2 2024.
Based on Balentine LLC's 13F filing for Q2 2024, filed 7 Aug 2024.